Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $23.78

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been given a consensus recommendation of “Moderate Buy” by the thirteen brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $23.7778.

A number of research analysts recently weighed in on the company. Morgan Stanley boosted their target price on Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, December 18th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 20th. Finally, UBS Group lifted their target price on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, November 6th.

Elanco Animal Health Stock Up 0.5%

Shares of ELAN stock opened at $22.75 on Friday. Elanco Animal Health has a 52-week low of $8.02 and a 52-week high of $23.70. The stock has a market cap of $11.30 billion, a price-to-earnings ratio of 379.26, a PEG ratio of 3.47 and a beta of 1.86. The firm’s 50-day moving average is $22.14 and its 200-day moving average is $18.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.Elanco Animal Health’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the company posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Sell-side analysts predict that Elanco Animal Health will post 0.91 EPS for the current year.

Insider Transactions at Elanco Animal Health

In other news, insider Rajeev A. Modi purchased 4,500 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the purchase, the insider directly owned 123,082 shares of the company’s stock, valued at $2,625,339.06. This trade represents a 3.79% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was purchased at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the acquisition, the director owned 131,773 shares in the company, valued at approximately $2,806,764.90. This represents a 8.21% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 43,450 shares of company stock worth $937,883. Insiders own 0.89% of the company’s stock.

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. SJS Investment Consulting Inc. boosted its position in shares of Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares during the period. Huntington National Bank raised its stake in Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after purchasing an additional 1,087 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after purchasing an additional 900 shares during the period. Farther Finance Advisors LLC grew its position in shares of Elanco Animal Health by 79.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares in the last quarter. Finally, Fifth Third Bancorp increased its holdings in shares of Elanco Animal Health by 3,018.3% during the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after purchasing an additional 2,807 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.